U.S. Markets close in 2 hrs 32 mins
  • S&P 500

    4,144.16
    -35.60 (-0.85%)
     
  • Dow 30

    33,900.64
    -153.30 (-0.45%)
     
  • Nasdaq

    12,074.73
    -126.09 (-1.03%)
     
  • Russell 2000

    1,989.45
    -11.77 (-0.59%)
     
  • Crude Oil

    73.64
    -2.24 (-2.95%)
     
  • Gold

    1,876.40
    -54.40 (-2.82%)
     
  • Silver

    22.38
    -1.24 (-5.25%)
     
  • EUR/USD

    1.0818
    -0.0093 (-0.8546%)
     
  • 10-Yr Bond

    3.5150
    +0.1190 (+3.50%)
     
  • Vix

    18.86
    +0.13 (+0.69%)
     
  • GBP/USD

    1.2067
    -0.0162 (-1.3273%)
     
  • USD/JPY

    131.0170
    +2.4130 (+1.8763%)
     
  • BTC-USD

    23,467.40
    -622.68 (-2.58%)
     
  • CMC Crypto 200

    537.16
    +0.30 (+0.06%)
     
  • FTSE 100

    7,901.80
    +81.64 (+1.04%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

EVANSTON, Ill., October 18, 2022--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights.

To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international) and refer to conference ID 141144. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has two product candidates in clinical development in central nervous system indications, including cognitive impairment and post-traumatic stress disorder. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221018005503/en/

Contacts

Investor & Media Contact:
Patrick Flavin
Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com
847-871-0377